Vis enkel innførsel

dc.contributor.advisorSørbye, Sveinung Wergeland
dc.contributor.advisorSimonsen, Gunnar Skov
dc.contributor.authorRiibe, Marit Østlyngen
dc.date.accessioned2022-09-05T07:46:03Z
dc.date.available2022-09-05T07:46:03Z
dc.date.issued2020-08-30
dc.description.abstractBackground/objective: Long-term follow-up of patients with positive tests for Human Papilloma Viruses (HPV) is rarely studied. The study objective was to compare HPV status at baseline with the outcome of CIN3+ in the follow-up period of 28 years. Materials and methods: All women referred to the HPV outpatient clinic at the University Hospital of Northern Norway (UNN) in 1990-1992, having a HPV test performed during that time, were included in this retrospective cohort. An exposed cohort with positive high-risk (HR) HPV test was compared to a control cohort with negative HR-HPV test. Both cohorts were followed up to the last time-point of observation of 28 years. Results: The risk of CIN2+ among HPV positive and HPV negative women was 57.0% (127/223) and 17.4% (73/419), respectively (p<0.01). Among the 223 HR-HPV positive women, 102 (45.7%) developed CIN3+, while 44 (10.5%) out of 419 HPV negative women developed CIN3+ (p<0.01). The overall cumulative incidence of CIN3+ was 22.7%. Women with HPV33 had the highest incidence of CIN3+, but HPV16 provided the greatest long-term risk of CIN3+. The incidence of CIN3+ was similar for women with a negative HR-HPV test and women with a positive low-risk (LR) HPV test, including HPV 6 and 11. Conclusion and consequences: HPV status at baseline is predictive for women ́s subsequent risk of developing CIN3+. Women with a positive HR-HPV test in 1990-1992 had a significantly higher risk of CIN3+ during 28 years of follow-up compared to HR-HPV negative women. The cumulative incidence of CIN3+ within the two groups were quite similar to that of CIN2+, suggesting that most women with prevalent CIN2+ also developed CIN3+. Our results suggests that detection of LR-HPV types does not predict CIN3+ and therefore should be omitted from primary screening for cervical cancer.en_US
dc.identifier.urihttps://hdl.handle.net/10037/26619
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)en_US
dc.subject.courseIDMED-3950
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gynekologi og obstetrikk: 756en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Gynecology and obstetrics: 756en_US
dc.titleRisk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) among women with HPV-test in 1990-1992en_US
dc.typeMaster thesisen_US
dc.typeMastergradsoppgaveen_US


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)